Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
8.16
+0.45 (5.84%)
At close: Mar 9, 2026, 4:00 PM EDT
8.28
+0.12 (1.47%)
After-hours: Mar 9, 2026, 6:28 PM EDT
Gyre Therapeutics Employees
Gyre Therapeutics had 579 employees as of December 31, 2024. The number of employees decreased by 14 or -2.36% compared to the previous year.
Employees
579
Change (1Y)
-14
Growth (1Y)
-2.36%
Revenue / Employee
$185,259
Profits / Employee
$11,487
Market Cap
741.67M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 579 | -14 | -2.36% |
| Dec 31, 2023 | 593 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Prime Medicine | 214 |
| ProKidney | 204 |
| Omeros | 202 |
| Lexicon Pharmaceuticals | 103 |
| Theravance Biopharma | 97 |
| AgomAb Therapeutics NV | 58 |
| Jade Biosciences | 55 |
GYRE News
- 7 days ago - Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting - GlobeNewsWire
- 4 months ago - Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis - GlobeNewsWire
- 5 months ago - Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 - GlobeNewsWire
- 6 months ago - Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 6 months ago - Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker - Benzinga
- 7 months ago - Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors - GlobeNewsWire